Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis

Kidney International

Volumn 96, Issue 2, 2019, Pages 302-319

  Barrera Chimal, Jonatan ^a   Girerd, Sophie ^b,c,d   Jaisser, Frederic ^c,d,e  

^a INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

^c UNIVERSITÉ DE LORRAINE   (France)

^d French Clinical Research Infrastructure Network (F CRIN)   (France)

^e SORBONNE UNIVERSITÉ   (France)

Author keywords

aldosterone; clinical study; fibrosis; inflammation; kidney injury

Indexed keywords

CALCINEURIN INHIBITOR; EPLERENONE; FINERENONE; MINERALOCORTICOID ANTAGONIST; SPIRONOLACTONE; MINERALOCORTICOID RECEPTOR;

ACUTE KIDNEY FAILURE; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; COMORBIDITY; DIABETIC NEPHROPATHY; DISEASE EXACERBATION; DRUG SAFETY; EVIDENCE BASED MEDICINE; GLOMERULONEPHRITIS; HEART FAILURE; HUMAN; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY TRANSPLANTATION; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEINURIA; RENAL ISCHEMIA REPERFUSION INJURY; RENAL PROTECTION; REVIEW; ANIMAL; BLOOD FLOW; CLINICAL TRIAL (TOPIC); DISEASE MODEL; DRUG EFFECT; GLOBAL DISEASE BURDEN; GLOBAL HEALTH; KIDNEY; METABOLISM; PATHOLOGY; PRECLINICAL STUDY; PREVALENCE; TREATMENT OUTCOME; VASCULARIZATION;

ACUTE KIDNEY INJURY; ANIMALS; CALCINEURIN INHIBITORS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG EVALUATION, PRECLINICAL; GLOBAL BURDEN OF DISEASE; GLOBAL HEALTH; HUMANS; KIDNEY; MINERALOCORTICOID RECEPTOR ANTAGONISTS; OXIDATIVE STRESS; PREVALENCE; RECEPTORS, MINERALOCORTICOID; REGIONAL BLOOD FLOW; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

EID: 85066071478     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2019.02.030     Document Type: Review

References (197)

1. Jaisser, F., Farman, N., Emerging roles of the mineralocorticoid receptor in pathology: toward new paradigms in clinical pharmacology. Pharmacol Rev 68 (2016), 49–75.
2. Caprio, M., Newfell, B.G., la Sala, A., et al. Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circ Res 102 (2008), 1359–1367.
3. Huang, L.L., Nikolic-Paterson, D.J., Han, Y., et al. Myeloid mineralocorticoid receptor activation contributes to progressive kidney disease. J Am Soc Nephrol 25 (2014), 2231–2240.
4. Nishiyama, A., Yao, L., Fan, Y., et al. Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability. Hypertension 45 (2005), 710–716.
5. Nagai, Y., Miyata, K., Sun, G.P., et al. Aldosterone stimulates collagen gene expression and synthesis via activation of ERK1/2 in rat renal fibroblasts. Hypertension 46 (2005), 1039–1045.
6. Rickard, A.J., Morgan, J., Tesch, G., et al. Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure. Hypertension 54 (2009), 537–543.
7. Usher, M.G., Duan, S.Z., Ivaschenko, C.Y., et al. Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Invest 120 (2010), 3350–3364.
8. Sun, X.N., Li, C., Liu, Y., et al. T-cell mineralocorticoid receptor controls blood pressure by regulating interferon-gamma. Circ Res 120 (2017), 1584–1597.
9. Armanini, D., Endres, S., Kuhnle, U., Weber, P.C., Parallel determination of mineralocorticoid and glucocorticoid receptors in T- and B-lymphocytes of human spleen. Acta Endocrinol (Copenh) 118 (1988), 479–482.
10. Ackermann, D., Gresko, N., Carrel, M., et al. In vivo nuclear translocation of mineralocorticoid and glucocorticoid receptors in rat kidney: differential effect of corticosteroids along the distal tubule. Am J Physiol Renal Physiol 299 (2010), F1473–F1485.
11. Nguyen Dinh Cat, A., Griol-Charhbili, V., Loufrani, L., et al. The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure. FASEB J 24 (2010), 2454–2463.
12. Jaffe, I.Z., Mendelsohn, M.E., Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ Res 96 (2005), 643–650.
13. Terada, Y., Kobayashi, T., Kuwana, H., et al. Aldosterone stimulates proliferation of mesangial cells by activating mitogen-activated protein kinase 1/2, cyclin D1, and cyclin A. J Am Soc Nephrol 16 (2005), 2296–2305.
14. Lim, H.Y., Muller, N., Herold, M.J., et al. Glucocorticoids exert opposing effects on macrophage function dependent on their concentration. Immunology 122 (2007), 47–53.
15. Gilmour, J.S., Coutinho, A.E., Cailhier, J.F., et al. Local amplification of glucocorticoids by 11 beta-hydroxysteroid dehydrogenase type 1 promotes macrophage phagocytosis of apoptotic leukocytes. J Immunol 176 (2006), 7605–7611.
16. Leopold, J.A., Dam, A., Maron, B.A., et al. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med 13 (2007), 189–197.
17. Maron, B.A., Zhang, Y.Y., White, K., et al. Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension. Circulation 126 (2012), 963–974.
18. Taye, A., Morawietz, H., Spironolactone inhibits NADPH oxidase-induced oxidative stress and enhances eNOS in human endothelial cells. Iran J Pharm Res 10 (2011), 329–337.
19. Callera, G.E., Touyz, R.M., Tostes, R.C., et al. Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src. Hypertension 45 (2005), 773–779.
20. Shibata, S., Nagase, M., Yoshida, S., et al. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension 49 (2007), 355–364.
21. Miyata, K., Rahman, M., Shokoji, T., et al. Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells. J Am Soc Nephrol 16 (2005), 2906–2912.
22. Mathew, J.T., Patni, H., Chaudhary, A.N., et al. Aldosterone induces mesangial cell apoptosis both in vivo and in vitro. Am J Physiol Renal Physiol 295 (2008), F73–F81.
23. Diah, S., Zhang, G.X., Nagai, Y., et al. Aldosterone induces myofibroblastic transdifferentiation and collagen gene expression through the Rho-kinase dependent signaling pathway in rat mesangial cells. Exp Cell Res 314 (2008), 3654–3662.
24. Brilla, C.G., Zhou, G., Matsubara, L., Weber, K.T., Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol 26 (1994), 809–820.
25. Zhou, G., Kandala, J.C., Tyagi, S.C., et al. Effects of angiotensin II and aldosterone on collagen gene expression and protein turnover in cardiac fibroblasts. Mol Cell Biochem 154 (1996), 171–178.
26. Irita, J., Okura, T., Kurata, M., et al. Osteopontin in rat renal fibroblasts: functional properties and transcriptional regulation by aldosterone. Hypertension 51 (2008), 507–513.
27. Calo, L.A., Zaghetto, F., Pagnin, E., et al. Effect of aldosterone and glycyrrhetinic acid on the protein expression of PAI-1 and p22(phox) in human mononuclear leukocytes. J Clin Endocrinol Metab 89 (2004), 1973–1976.
28. Buonafine, M., Martinez-Martinez, E., Amador, C., et al. Neutrophil gelatinase-associated lipocalin from immune cells is mandatory for aldosterone-induced cardiac remodeling and inflammation. J Mol Cell Cardiol 115 (2018), 32–38.
29. Cole, T.J., Young, M.J., 30 years of the mineralocorticoid receptor: mineralocorticoid receptor null mice: informing cell-type-specific roles. J Endocrinol 234 (2017), T83–T92.
30. Taira, M., Toba, H., Murakami, M., et al. Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats. Eur J Pharmacol 589 (2008), 264–271.
31. Quinkler, M., Zehnder, D., Eardley, K.S., et al. Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria. Circulation 112 (2005), 1435–1443.
32. Krug, A.W., Allenhofer, L., Monticone, R., et al. Elevated mineralocorticoid receptor activity in aged rat vascular smooth muscle cells promotes a proinflammatory phenotype via extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase and epidermal growth factor receptor-dependent pathways. Hypertension 55 (2010), 1476–1483.
33. DeLano, F.A., Schmid-Schonbein, G.W., Enhancement of glucocorticoid and mineralocorticoid receptor density in the microcirculation of the spontaneously hypertensive rat. Microcirculation 11 (2004), 69–78.
34. Kolkhof, P., Barfacker, L., 30 years of the mineralocorticoid receptor: Mineralocorticoid receptor antagonists: 60 years of research and development. J Endocrinol 234 (2017), T125–T140.
35. Kolkhof, P., Nowack, C., Eitner, F., Nonsteroidal antagonists of the mineralocorticoid receptor. Curr Opin Nephrol Hypertens 24 (2015), 417–424.
36. Mejía-Vilet, J.M., Ramirez, V., Cruz, C., et al. Renal ischemia-reperfusion injury is prevented by the mineralocorticoid receptor blocker spironolactone. Am J Physiol Renal Physiol 293 (2007), F78–F86.
37. Ramirez, V., Trujillo, J., Valdes, R., et al. Adrenalectomy prevents renal ischemia-reperfusion injury. Am J Physiol Renal Physiol 297 (2009), F932–F942.
38. Sanchez-Pozos, K., Barrera-Chimal, J., Garzon-Muvdi, J., et al. Recovery from ischemic acute kidney injury by spironolactone administration. Nephrol Dial Transplant 27 (2012), 3160–3169.
39. Barrera-Chimal, J., Prince, S., Fadel, F., et al. Sulfenic acid modification of endothelin B receptor is responsible for the benefit of a nonsteroidal mineralocorticoid receptor antagonist in renal ischemia. J Am Soc Nephrol 27 (2016), 398–404.
40. Lattenist, L., Lechner, S.M., Messaoudi, S., et al. Nonsteroidal mineralocorticoid receptor antagonist finerenone protects against acute kidney injury-mediated chronic kidney disease: role of oxidative stress. Hypertension 69 (2017), 870–878.
41. Barrera-Chimal, J., Andre-Gregoire, G., Nguyen Dinh Cat, A., et al. Benefit of mineralocorticoid receptor antagonism in AKI: role of vascular smooth muscle Rac1. J Am Soc Nephrol 28 (2017), 1216–1226.
42. Ozacmak, H.S., Ozacmak, V.H., Barut, F., et al. Pretreatment with mineralocorticoid receptor blocker reduces intestinal injury induced by ischemia and reperfusion: involvement of inhibition of inflammatory response, oxidative stress, nuclear factor kappaB, and inducible nitric oxide synthase. J Surg Res 191 (2014), 350–361.
43. Oyamada, N., Sone, M., Miyashita, K., et al. The role of mineralocorticoid receptor expression in brain remodeling after cerebral ischemia. Endocrinology 149 (2008), 3764–3777.
44. Kang, Y.M., Zhang, Z.H., Johnson, R.F., et al. Novel effect of mineralocorticoid receptor antagonism to reduce proinflammatory cytokines and hypothalamic activation in rats with ischemia-induced heart failure. Circ Res 99 (2006), 758–766.
45. Fiorentino, M., Grandaliano, G., Gesualdo, L., Castellano, G., Acute kidney injury to chronic kidney disease transition. Contrib Nephrol 193 (2018), 45–54.
46. Barrera-Chimal, J., Perez-Villalva, R., Rodriguez-Romo, R., et al. Spironolactone prevents chronic kidney disease caused by ischemic acute kidney injury. Kidney Int 83 (2013), 93–103.
47. Barrera-Chimal, J., Rocha, L., Amador-Martinez, I., et al. Delayed spironolactone administration prevents the transition from acute kidney injury to chronic kidney disease through improving renal inflammation. Nephrol Dial Transplant, 2018.
48. Barrera-Chimal, J., Perez-Villalva, R., Ortega, J.A., et al. Mild ischemic injury leads to long-term alterations in the kidney: amelioration by spironolactone administration. Int J Biol Sci 11 (2015), 892–900.
49. Frieler, R.A., Ray, J.J., Meng, H., et al. Myeloid mineralocorticoid receptor during experimental ischemic stroke: effects of model and sex. J Am Heart Assoc, 1, 2012, e002584.
50. Frieler, R.A., Meng, H., Duan, S.Z., et al. Myeloid-specific deletion of the mineralocorticoid receptor reduces infarct volume and alters inflammation during cerebral ischemia. Stroke 42 (2011), 179–185.
51. Shen, J.Z., Morgan, J., Tesch, G.H., et al. Cardiac tissue injury and remodeling is dependent upon MR regulation of activation pathways in cardiac tissue macrophages. Endocrinology 157 (2016), 3213–3223.
52. Li, C., Zhang, Y.Y., Frieler, R.A., et al. Myeloid mineralocorticoid receptor deficiency inhibits aortic constriction-induced cardiac hypertrophy in mice. PLoS One, 9, 2014, e110950.
53. Rafatian, N., Westcott, K.V., White, R.A., Leenen, F.H., Cardiac macrophages and apoptosis after myocardial infarction: effects of central MR blockade. Am J Physiol Regul Integr Comp Physiol 307 (2014), R879–R887.
54. Greene, E.L., Kren, S., Hostetter, T.H., Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 98 (1996), 1063–1068.
55. Aldigier, J.C., Kanjanbuch, T., Ma, L.J., et al. Regression of existing glomerulosclerosis by inhibition of aldosterone. J Am Soc Nephrol 16 (2005), 3306–3314.
56. Fujihara, C.K., Kowala, M.C., Breyer, M.D., et al. A novel aldosterone antagonist limits renal injury in 5/6 nephrectomy. Sci Rep, 7, 2017, 7899.
57. Nagase, M., Shibata, S., Yoshida, S., et al. Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension 47 (2006), 1084–1093.
58. Arai, K., Tsuruoka, H., Homma, T., CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats. Eur J Pharmacol 769 (2015), 266–273.
59. Shibata, S., Nagase, M., Yoshida, S., et al. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med 14 (2008), 1370–1376.
60. Asai, M., Monkawa, T., Marumo, T., et al. Spironolactone in combination with cilazapril ameliorates proteinuria and renal interstitial fibrosis in rats with anti-Thy-1 irreversible nephritis. Hypertens Res 27 (2004), 971–978.
61. Gullulu, M., Akdag, I., Kahvecioglu, S., et al. Aldosterone blockage in proliferative glomerulonephritis prevents not only fibrosis, but proliferation as well. Ren Fail 28 (2006), 509–514.
62. Qin, D., Morita, H., Inui, K., et al. Aldosterone mediates glomerular inflammation in experimental mesangial proliferative glomerulonephritis. J Nephrol 26 (2013), 199–206.
63. Zitt, E., Eller, K., Huber, J.M., et al. The selective mineralocorticoid receptor antagonist eplerenone is protective in mild anti-GBM glomeru-lonephritis. Int J Clin Exp Pathol 4 (2011), 606–615.
64. Ma, F.Y., Han, Y., Nikolic-Paterson, D.J., et al. Suppression of rapidly progressive mouse glomerulonephritis with the non-steroidal mineralocorticoid receptor antagonist BR-4628. PLoS One, 10, 2015, e0145666.
65. Rocha, R., Chander, P.N., Zuckerman, A., Stier, C.T. Jr., Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 33 (1999), 232–237.
66. Brown, N.J., Nakamura, S., Ma, L., et al. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 58 (2000), 1219–1227.
67. Zhou, X., Ono, H., Ono, Y., Frohlich, E.D., Aldosterone antagonism ameliorates proteinuria and nephrosclerosis independent of glomerular dynamics in L-NAME/SHR model. Am J Nephrol 24 (2004), 242–249.
68. Ikeda, H., Tsuruya, K., Toyonaga, J., et al. Spironolactone suppresses inflammation and prevents L-NAME-induced renal injury in rats. Kidney Int 75 (2009), 147–155.
69. Blasi, E.R., Rocha, R., Rudolph, A.E., et al. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 63 (2003), 1791–1800.
70. Nariai, T., Fujita, K., Mori, M., et al. Antihypertensive and cardiorenal protective effects of SM-368229, a novel mineralocorticoid receptor antagonist, in aldosterone/salt-treated rats. Pharmacology 89 (2012), 44–52.
71. Bamberg, K., Johansson, U., Edman, K., et al. Preclinical pharmacology of AZD9977: a novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion. PLoS One, 13, 2018, e0193380.
72. Arai, K., Morikawa, Y., Ubukata, N., et al. CS-3150, a novel nonsteroidal mineralocorticoid receptor antagonist, shows preventive and therapeutic effects on renal injury in deoxycorticosterone acetate/salt-induced hypertensive rats. J Pharmacol Exp Ther 358 (2016), 548–557.
73. Lother, A., Furst, D., Bergemann, S., et al. Deoxycorticosterone acetate/salt-induced cardiac but not renal injury is mediated by endothelial mineralocorticoid receptors independently from blood pressure. Hypertension 67 (2016), 130–138.
74. Trachtman, H., Weiser, A.C., Valderrama, E., et al. Prevention of renal fibrosis by spironolactone in mice with complete unilateral ureteral obstruction. J Urol 172 (2004), 1590–1594.
75. Chen, H., Sun, F., Zhong, X., et al. Eplerenone-mediated aldosterone blockade prevents renal fibrosis by reducing renal inflammation, interstitial cell proliferation and oxidative stress. Kidney Blood Press Res 37 (2013), 557–566.
76. Wang, C.H., Wang, Z., Liang, L.J., et al. The inhibitory effect of eplerenone on cell proliferation in the contralateral kidneys of rats with unilateral ureteral obstruction. Nephronology 136 (2017), 328–338.
77. Keri, K.C., Samji, N.S., Blumenthal, S., Diabetic nephropathy: newer therapeutic perspectives. J Community Hosp Intern Med Perspect 8 (2018), 200–207.
78. Fujisawa, G., Okada, K., Muto, S., et al. Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats. Kidney Int 66 (2004), 1493–1502.
79. Guo, C., Martinez-Vasquez, D., Mendez, G.P., et al. Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus. Endocrinology 147 (2006), 5363–5373.
80. Yuan, J., Jia, R., Bao, Y., Beneficial effects of spironolactone on glomerular injury in streptozotocin-induced diabetic rats. J Renin Angiotensin Aldosterone Syst 8 (2007), 118–126.
81. Banki, N.F., Ver, A., Wagner, L.J., et al. Aldosterone antagonists in monotherapy are protective against streptozotocin-induced diabetic nephropathy in rats. PLoS One, 7, 2012, e39938.
82. Lian, M., Hewitson, T.D., Wigg, B., et al. Long-term mineralocorticoid receptor blockade ameliorates progression of experimental diabetic renal disease. Nephrol Dial Transplant 27 (2012), 906–912.
83. Pessoa, B.S., Peixoto, E.B., Papadimitriou, A., et al. Spironolactone improves nephropathy by enhancing glucose-6-phosphate dehydrogenase activity and reducing oxidative stress in diabetic hypertensive rat. J Renin Angiotensin Aldosterone Syst 13 (2012), 56–66.
84. Zhou, G., Johansson, U., Peng, X.R., et al. An additive effect of eplerenone to ACE inhibitor on slowing the progression of diabetic nephropathy in the db/db mice. Am J Transl Res 8 (2016), 1339–1354.
85. Han, S.Y., Kim, C.H., Kim, H.S., et al. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J Am Soc Nephrol 17 (2006), 1362–1372.
86. Kang, Y.S., Ko, G.J., Lee, M.H., et al. Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats. Nephrol Dial Transplant 24 (2009), 73–84.
87. Nishiyama, A., Kobori, H., Konishi, Y., et al. Mineralocorticoid receptor blockade enhances the antiproteinuric effect of an angiotensin II blocker through inhibiting podocyte injury in type 2 diabetic rats. J Pharmacol Exp Ther 332 (2010), 1072–1080.
88. Lachaux, M., Barrera-Chimal, J., Nicol, L., et al. Short- and long-term administration of the non-steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome-related cardio-renal dysfunction. Diabetes Obes Metab 20 (2018), 2399–2407.
89. Nagase, M., Matsui, H., Shibata, S., et al. Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress. Hypertension 50 (2007), 877–883.
90. Tokuyama, H., Wakino, S., Hara, Y., et al. Role of mineralocorticoid receptor/Rho/Rho-kinase pathway in obesity-related renal injury. Int J Obes (Lond) 36 (2012), 1062–1071.
91. Yoshida, S., Ishizawa, K., Ayuzawa, N., et al. Local mineralocorticoid receptor activation and the role of Rac1 in obesity-related diabetic kidney disease. Nephron Exp Nephrol 126 (2014), 16–24.
92. Bobadilla, N.A., Gamba, G., New insights into the pathophysiology of cyclosporine nephrotoxicity: a role of aldosterone. Am J Physiol Renal Physiol 293 (2007), F2–F9.
93. McAuley, F.T., Whiting, P.H., Thomson, A.W., Simpson, J.G., The influence of enalapril or spironolactone on experimental cyclosporin nephrotoxicity. Biochem Pharmacol 36 (1987), 699–703.
94. Pérez-Rojas, J.M., Derive, S., Blanco, J.A., et al. Renocortical mRNA expression of vasoactive factors during spironolactone protective effect in chronic cyclosporine nephrotoxicity. Am J Physiol Renal Physiol 289 (2005), F1020–F1030.
95. Nielsen, F.T., Jensen, B.L., Marcussen, N., et al. Inhibition of mineralocorticoid receptors with eplerenone alleviates short-term cyclosporin A nephrotoxicity in conscious rats. Nephrol Dial Transplant 23 (2008), 2777–2783.
96. Amador, C.A., Bertocchio, J.P., Andre-Gregoire, G., et al. Deletion of mineralocorticoid receptors in smooth muscle cells blunts renal vascular resistance following acute cyclosporine administration. Kidney Int 89 (2016), 354–362.
97. Feria, I., Pichardo, I., Juarez, P., et al. Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity. Kidney Int 63 (2003), 43–52.
98. Nielsen, F.T., Jensen, B.L., Hansen, P.B., et al. The mineralocorticoid receptor antagonist eplerenone reduces renal interstitial fibrosis after long-term cyclosporine treatment in rat: antagonizing cyclosporine nephrotoxicity. BMC Nephrol, 14, 2013, 42.
99. Pérez-Rojas, J., Blanco, J.A., Cruz, C., et al. Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity. Am J Physiol Renal Physiol 292 (2007), F131–F139.
100. Waanders, F., Rienstra, H., Boer, M.W., et al. Spironolactone ameliorates transplant vasculopathy in renal chronic transplant dysfunction in rats. Am J Physiol Renal Physiol 296 (2009), F1072–F1079.
101. Lahmer, T., Hermans, R., Schmaderer, C., et al. Mineralocorticoid receptor antagonism and aldosterone synthesis inhibition do not improve glomerulosclerosis and renal interstitial fibrosis in a model of chronic kidney allograft injury. Kidney Blood Press Res 35 (2012), 561–567.
102. Michea, L., Villagran, A., Urzua, A., et al. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and prevents oxidative stress in uremic rats. Hypertension 52 (2008), 295–300.
103. Bonnard, B., Pieronne-Deperrois, M., Djerada, Z., et al. Mineralocorticoid receptor antagonism improves diastolic dysfunction in chronic kidney disease in mice. J Mol Cell Cardiol 121 (2018), 124–133.
104. Bostick, B., Habibi, J., DeMarco, V.G., et al. Mineralocorticoid receptor blockade prevents Western diet-induced diastolic dysfunction in female mice. Am J Physiol Heart Circ Physiol 308 (2015), H1126–H1135.
105. Jia, G., Habibi, J., Aroor, A.R., et al. Endothelial mineralocorticoid receptor mediates diet-induced aortic stiffness in females. Circ Res 118 (2016), 935–943.
106. Takata, H., Takeda, Y., Zhu, A., et al. Protective effects of mineralocorticoid receptor blockade against neuropathy in experimental diabetic rats. Diabetes Obes Metab 14 (2012), 155–162.
107. Schupp, N., Kolkhof, P., Queisser, N., et al. Mineralocorticoid receptor-mediated DNA damage in kidneys of DOCA-salt hypertensive rats. FASEB J 25 (2011), 968–978.
108. Nishiyama, A., Yao, L., Nagai, Y., et al. Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats. Hypertension 43 (2004), 841–848.
109. Keidar, S., Kaplan, M., Pavlotzky, E., et al. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation 109 (2004), 2213–2220.
110. Iwashima, F., Yoshimoto, T., Minami, I., et al. Aldosterone induces superoxide generation via Rac1 activation in endothelial cells. Endocrinology 149 (2008), 1009–1014.
111. Fiebeler, A., Luft, F.C., The mineralocorticoid receptor and oxidative stress. Heart Fail Rev 10 (2005), 47–52.
112. Min, L.J., Mogi, M., Iwanami, J., et al. Cross-talk between aldosterone and angiotensin II in vascular smooth muscle cell senescence. Cardiovasc Res 76 (2007), 506–516.
113. McCurley, A., Pires, P.W., Bender, S.B., et al. Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors. Nat Med 18 (2012), 1429–1433.
114. Petramala, L., Pignatelli, P., Carnevale, R., et al. Oxidative stress in patients affected by primary aldosteronism. J Hypertens 32 (2014), 2022–2029; discussion 2029.
115. Ojeda-Cervantes, M., Barrera-Chimal, J., Alberu, J., et al. Mineralocorticoid receptor blockade reduced oxidative stress in renal transplant recipients: a double-blind, randomized pilot study. Am J Nephrol 37 (2013), 481–490.
116. Takebayashi, K., Matsumoto, S., Aso, Y., Inukai, T., Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. J Clin Endocrinol Metab 91 (2006), 2214–2217.
117. Miura, R., Nakamura, K., Miura, D., et al. Anti-inflammatory effect of spironolactone on human peripheral blood mononuclear cells. J Pharmacol Sci 101 (2006), 256–259.
118. Montes-Cobos, E., Schweingruber, N., Li, X., et al. Deletion of the mineralocorticoid receptor in myeloid cells attenuates central nervous system autoimmunity. Front Immunol, 8, 2017, 1319.
119. Sun, J.Y., Li, C., Shen, Z.X., et al. Mineralocorticoid receptor deficiency in macrophages inhibits neointimal hyperplasia and suppresses macrophage inflammation through SGK1-AP1/NF-kappaB pathways. Arterioscler Thromb Vasc Biol 36 (2016), 874–885.
120. Amador, C.A., Barrientos, V., Pena, J., et al. Spironolactone decreases DOCA-salt-induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes. Hypertension 63 (2014), 797–803.
121. Herrada, A.A., Contreras, F.J., Marini, N.P., et al. Aldosterone promotes autoimmune damage by enhancing Th17-mediated immunity. J Immunol 184 (2010), 191–202.
122. Sun, Y., Zhang, J., Zhang, J.Q., Ramires, F.J., Local angiotensin II and transforming growth factor-beta1 in renal fibrosis of rats. Hypertension 35 (2000), 1078–1084.
123. Martin-Fernandez, B., Rubio-Navarro, A., Cortegano, I., et al. Aldosterone induces renal fibrosis and inflammatory M1-macrophage subtype via mineralocorticoid receptor in rats. PLoS One, 11, 2016, e0145946.
124. Chen, D., Chen, Z., Park, C., et al. Aldosterone stimulates fibronectin synthesis in renal fibroblasts through mineralocorticoid receptor-dependent and independent mechanisms. Gene 531 (2013), 23–30.
125. Irita, J., Okura, T., Manabe, S., et al. Plasma osteopontin levels are higher in patients with primary aldosteronism than in patients with essential hypertension. Am J Hypertens 19 (2006), 293–297.
126. Huang, L.L., Nikolic-Paterson, D.J., Ma, F.Y., Tesch, G.H., Aldosterone induces kidney fibroblast proliferation via activation of growth factor receptors and PI3K/MAPK signalling. Nephron Exp Nephrol 120 (2012), e115–e122.
127. Galmiche, G., Pizard, A., Gueret, A., et al. Smooth muscle cell mineralocorticoid receptors are mandatory for aldosterone-salt to induce vascular stiffness. Hypertension 63 (2014), 520–526.
128. Calvier, L., Miana, M., Reboul, P., et al. Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler Thromb Vasc Biol 33 (2013), 67–75.
129. Pruthi, D., McCurley, A., Aronovitz, M., et al. Aldosterone promotes vascular remodeling by direct effects on smooth muscle cell mineralocorticoid receptors. Arterioscler Thromb Vasc Biol 34 (2014), 355–364.
130. Tarjus, A., Martinez-Martinez, E., Amador, C., et al. Neutrophil gelatinase-associated lipocalin, a novel mineralocorticoid biotarget, mediates vascular profibrotic effects of mineralocorticoids. Hypertension 66 (2015), 158–166.
131. Martinez-Martinez, E., Buonafine, M., Boukhalfa, I., et al. Aldosterone target NGAL (neutrophil gelatinase-associated lipocalin) is involved in cardiac remodeling after myocardial infarction through NFkappaB pathway. Hypertension 70 (2017), 1148–1156.
132. Calvier, L., Martinez-Martinez, E., Miana, M., et al. The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries. JACC Heart Fail 3 (2015), 59–67.
133. Artunc, F., Lang, F., Mineralocorticoid and SGK1-sensitive inflammation and tissue fibrosis. Nephron Physiol 128 (2014), 35–39.
134. Krug, A.W., Grossmann, C., Schuster, C., et al. Aldosterone stimulates epidermal growth factor receptor expression. J Biol Chem 278 (2003), 43060–43066.
135. Bolignano, D., Palmer, S.C., Navaneethan, S.D., Strippoli, G.F., Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev, 2014, CD007004.
136. Currie, G., Taylor, A.H., Fujita, T., et al. Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis. BMC Nephrol, 17, 2016, 127.
137. Hou, J., Xiong, W., Cao, L., et al. Spironolactone add-on for preventing or slowing the progression of diabetic nephropathy: a meta-analysis. Clin Ther 37 (2015), 2086–2103.e10.
138. Bakris, G.L., Agarwal, R., Chan, J.C., et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA 314 (2015), 884–894.
139. Bianchi, S., Bigazzi, R., Campese, V.M., Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 70 (2006), 2116–2123.
140. Boesby, L., Elung-Jensen, T., Klausen, T.W., et al. Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study. PLoS One, 6, 2011, e26904.
141. Heerspink, H.J., Kropelin, T.F., Hoekman, J., de Zeeuw, D., Drug-induced reduction in albuminuria is associated with subsequent renoprotection: a meta-analysis. J Am Soc Nephrol 26 (2015), 2055–2064.
142. Avasare, R.S., Radhakrishnan, J., Proteinuria as a surrogate marker for renal outcome: Are we there yet?. Kidney Int 88 (2015), 1228–1230.
143. Levey, A.S., Cattran, D., Friedman, A., et al. Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 54 (2009), 205–226.
144. US Food and Drug Administration, Table of surrogate endpoints that were the basis of drug approval or licensure. Available at: https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm613636.htm Accessed July 2, 2019.
145. Roy-Chaudhury, P., Exploring novel endpoints for clinical trials in kidney disease: challenges and opportunities. Kidney Int Rep 2 (2017), 295–296.
146. Strippoli, G.F., Craig, J.C., Schena, F.P., The number, quality, and coverage of randomized controlled trials in nephrology. J Am Soc Nephrol 15 (2004), 411–419.
147. Levey, A.S., Inker, L.A., Matsushita, K., et al. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 64 (2014), 821–835.
148. Zannad, F., Gattis Stough, W., Rossignol, P., et al. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J 33 (2012), 2782–2795.
149. Ponikowski, P., Voors, A.A., Anker, S.D., et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37 (2016), 2129–2200.
150. Girerd, N., Ferreira, J.P., Rossignol, P., Zannad, F., A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis. Eur J Heart Fail 18 (2016), 1411–1414.
151. Eschalier, R., McMurray, J.J., Swedberg, K., et al. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (eplerenone in mild patients hospitalization and survival study in heart failure). J Am Coll Cardiol 62 (2013), 1585–1593.
152. Löfman, I., Szummer, K., Olsson, H., et al. Association between mineralocorticoid receptor antagonist use and outcome in myocardial infarction patients with heart failure. J Am Heart Assoc, 7, 2018 pii: e009359.
153. Pitt, B., Kober, L., Ponikowski, P., et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J 34 (2013), 2453–2463.
154. Edwards, N.C., Steeds, R.P., Stewart, P.M., et al. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. J Am Coll Cardiol 54 (2009), 505–512.
155. Edwards, N.C., Ferro, C.J., Kirkwood, H., et al. Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease. Am J Cardiol 106 (2010), 1505–1511.
156. Boesby, L., Elung-Jensen, T., Strandgaard, S., Kamper, A.L., Eplerenone attenuates pulse wave reflection in chronic kidney disease stage 3-4—a randomized controlled study. PLoS One, 8, 2013, e64549.
157. DuPont, J.J., Jaffe, I.Z., 30 years of the mineralocorticoid receptor: the role of the mineralocorticoid receptor in the vasculature. J Endocrinol 234 (2017), T67–T82.
158. Taheri, S., Mortazavi, M., Shahidi, S., et al. Spironolactone in chronic hemodialysis patients improves cardiac function. Saudi J Kidney Dis Transpl 20 (2009), 392–397.
159. Taheri, S., Mortazavi, M., Pourmoghadas, A., et al. A prospective double-blind randomized placebo-controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis. Saudi J Kidney Dis Transpl 23 (2012), 507–512.
160. Sood, M.M., Pauly, R.P., Rigatto, C., Komenda, P., Left ventricular dysfunction in the haemodialysis population. NDT Plus 1 (2008), 199–205.
161. Hammer, F., Malzahn, U., Donhauser, J., et al. A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients. Kidney Int 95 (2019), 938–991.
162. Charytan, D.M., Himmelfarb, J., Ikizler, T.A., et al. Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial. Kidney Int, 2018 pii: S0085-2538(18)30641-0.
163. Quach, K., Lvtvyn, L., Baigent, C., et al. The safety and efficacy of mineralocorticoid receptor antagonists in patients who require dialysis: a systematic review and meta-analysis. Am J Kidney Dis 68 (2016), 591–598.
164. Hill, N.R., Lasserson, D., Thompson, B., et al. Benefits of aldosterone receptor antagonism in chronic kidney disease (BARACK D) trial-a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial. Trials, 15, 2014, 160.
165. Ng, K.P., Jain, P., Heer, G., et al. Spironolactone to prevent cardiovascular events in early-stage chronic kidney disease (STOP-CKD): study protocol for a randomized controlled pilot trial. Trials, 15, 2014, 158.
166. Ng, K.P., Jain, P., Gill, P.S., et al. Results and lessons from the Spironolactone To Prevent Cardiovascular Events in Early Stage Chronic Kidney Disease (STOP-CKD) randomised controlled trial. BMJ Open, 6, 2016, e010519.
167. Girerd, S., Frimat, L., Ducloux, D., et al. EPURE Transplant (Eplerenone in Patients Undergoing Renal Transplant) Study: study protocol for a randomized controlled trial. Trials, 19, 2018, 595.
168. Medeiros, M., Velasquez-Jones, L., Hernandez, A.M., et al. Randomized controlled trial of mineralocorticoid receptor blockade in children with chronic kidney allograft nephropathy. Clin J Am Soc Nephrol 12 (2017), 1291–1300.
169. Mortensen, L.A., Thiesson, H.C., Tougaard, B., et al. The effect of spironolactone on calcineurin inhibitor induced nephrotoxicity: a multicenter randomized, double-blind, clinical trial (the SPIREN trial). BMC Nephrol, 19, 2018, 105.
170. Barba-Navarro, R., Tapia-Silva, M., Garza-Garcia, C., et al. The effect of spironolactone on acute kidney injury after cardiac surgery: a randomized, placebo-controlled trial. Am J Kidney Dis 69 (2017), 192–199.
171. Pretorius, M., Murray, K.T., Yu, C., et al. Angiotensin-converting enzyme inhibition or mineralocorticoid receptor blockade do not affect prevalence of atrial fibrillation in patients undergoing cardiac surgery. Crit Care Med 40 (2012), 2805–2812.
172. Mujtaba, A., Taher, M.A., Hazza, M.A., et al. The effect of spironolactone on the incidence of contrast-induced nephropathy in patients undergoing cardiac catheterization: study design and rationale. Cardiol Ther 7 (2018), 101–106.
173. Bomback, A.S., Klemmer, P.J., The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 3 (2007), 486–492.
174. Sato, A., Hayashi, K., Naruse, M., Saruta, T., Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 41 (2003), 64–68.
175. Schjoedt, K.J., Andersen, S., Rossing, P., et al. Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 47 (2004), 1936–1939.
176. Bakris, G., Burgess, E., Weir, M., et al. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int 74 (2008), 364–369.
177. Moranne, O., Bakris, G., Fafin, C., et al. Determinants and changes associated with aldosterone breakthrough after angiotensin II receptor blockade in patients with type 2 diabetes with overt nephropathy. Clin J Am Soc Nephrol 8 (2013), 1694–1701.
178. Esteghamati, A., Noshad, S., Jarrah, S., et al. Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial. Nephrol Dial Transplant 28 (2013), 2823–2833.
179. Maggioni, A.P., Anker, S.D., Dahlstrom, U., et al. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 15 (2013), 1173–1184.
180. Williams, B., Mancia, G., Spiering, W., et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J 39 (2018), 3021–3104.
181. Sarwar, C.M., Papadimitriou, L., Pitt, B., et al. Hyperkalemia in heart failure. J Am Coll Cardiol 68 (2016), 1575–1589.
182. Vukadinovic, D., Lavall, D., Vukadinovic, A.N., et al. True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: a meta-analysis. Am Heart J 188 (2017), 99–108.
183. Gonzalez Monte, E., Andres, A., Polanco, N., et al. Addition of spironolactone to dual blockade of renin angiotensin system dramatically reduces severe proteinuria in renal transplant patients: an uncontrolled pilot study at 6 months. Transplant Proc 42 (2010), 2899–2901.
184. Bertocchio, J.P., Barbe, C., Lavaud, S., et al. Safety of eplerenone for kidney-transplant recipients with impaired renal function and receiving cyclosporine A. PLoS One, 11, 2016, e0153635.
185. Trevisan, M., de Deco, P., Xu, H., et al. Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists. Eur J Heart Fail 20 (2018), 1217–1226.
186. Cooper, L.B., Hammill, B.G., Peterson, E.D., et al. Characterization of mineralocorticoid receptor antagonist therapy initiation in high-risk patients with heart failure. Circ Cardiovasc Qual Outcomes, 10, 2017.
187. Roscioni, S.S., de Zeeuw, D., Bakker, S.J., Lambers Heerspink, H.J., Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy. Nat Rev Nephrol 8 (2012), 691–699.
188. Weir, M.R., Bakris, G.L., Bushinsky, D.A., et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med 372 (2015), 211–221.
189. Pitt, B., Bakris, G.L., Weir, M.R., et al. Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN. ESC Heart Fail 5 (2018), 592–602.
190. Georgianos, P.I., Agarwal, R., Revisiting RAAS blockade in CKD with newer potassium-binding drugs. Kidney Int 93 (2018), 325–334.
191. Packham, D.K., Rasmussen, H.S., Lavin, P.T., et al. Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med 372 (2015), 222–231.
192. Kosiborod, M., Rasmussen, H.S., Lavin, P., et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA 312 (2014), 2223–2233.
193. Pitt, B., Bakris, G.L., New potassium binders for the treatment of hyperkalemia: current data and opportunities for the future. Hypertension 66 (2015), 731–738.
194. Kolkhof, P., Delbeck, M., Kretschmer, A., et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol 64 (2014), 69–78.
195. Orena, S., Maurer, T.S., She, L., et al. PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy. Front Pharmacol, 4, 2013, 115.
196. Liu, L.C., Schutte, E., Gansevoort, R.T., et al. Finerenone: third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease. Expert Opin Investig Drugs 24 (2015), 1123–1135.
197. Kolkhof, P., Jaisser, F., Kim, S.Y., et al. Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: comparison at bench and bedside. Handb Exp Pharmacol 243 (2017), 271–305.